Haematologia Pub Date : 2019-12-20 DOI:10.5603/hem.2019.0027
Karolina Piechna, Przemyslaw Juszczynski
{"title":"Mechanizmy działania i strategie oporności komórek nowotworowych przeciwko apoptozie indukowanej przez TRAIL","authors":"Karolina Piechna, Przemyslaw Juszczynski","doi":"10.5603/hem.2019.0027","DOIUrl":null,"url":null,"abstract":"TRAIL (TNF-related apoptosis inducing ligand), a protein belonging to the tumor necrosis factor family, causes apoptosis induction through activation of its cognate death receptors (DR4, DR5). Binding TRAIL leads to induction of extrinsic or, in some cell types, intrinsic apoptosis pathways. Because of the lower death receptors surface expression on non-transformed cells than on cancer cells, DR4 and DR5 ligands attract a lot of attention as potential anti-cancer drugs. Despite exhibiting high activity in preclinical in vitro and in vivo models, in clinical trials TRAIL treatment proved to be inefficient. Lack of apoptotic activity is caused by intrinsic or secondary resistance to TRAIL, that is observed in cancer cells. Herein, we systematically review the resistance mechanisms to death-receptor triggered apoptosis. Identification of such mechanisms in clinical setting might serve as a “negative” biomarker, excluding patients unlikely to benefit from TRAIL-based therapies or present a possibility of pharmacological modulation.","PeriodicalId":12837,"journal":{"name":"Haematologia","volume":"14 1","pages":"135-147"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/hem.2019.0027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

TRAIL (tnf相关凋亡诱导配体)是肿瘤坏死因子家族的一种蛋白,通过激活其同源死亡受体(DR4, DR5)诱导细胞凋亡。结合TRAIL可诱导外源性或某些细胞类型的内在凋亡途径。由于在非转化细胞上死亡受体表面的表达量低于在癌细胞上,DR4和DR5配体作为潜在的抗癌药物备受关注。尽管在临床前体外和体内模型中表现出高活性,但在临床试验中,TRAIL治疗被证明是低效的。缺乏凋亡活性是由于对TRAIL的内在或继发性耐药引起的,这在癌细胞中观察到。在此,我们系统地回顾了死亡受体引发的细胞凋亡的抵抗机制。在临床环境中识别这种机制可能作为“阴性”生物标志物,排除不太可能从trail治疗中获益的患者或提供药理学调节的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mechanizmy działania i strategie oporności komórek nowotworowych przeciwko apoptozie indukowanej przez TRAIL
TRAIL (TNF-related apoptosis inducing ligand), a protein belonging to the tumor necrosis factor family, causes apoptosis induction through activation of its cognate death receptors (DR4, DR5). Binding TRAIL leads to induction of extrinsic or, in some cell types, intrinsic apoptosis pathways. Because of the lower death receptors surface expression on non-transformed cells than on cancer cells, DR4 and DR5 ligands attract a lot of attention as potential anti-cancer drugs. Despite exhibiting high activity in preclinical in vitro and in vivo models, in clinical trials TRAIL treatment proved to be inefficient. Lack of apoptotic activity is caused by intrinsic or secondary resistance to TRAIL, that is observed in cancer cells. Herein, we systematically review the resistance mechanisms to death-receptor triggered apoptosis. Identification of such mechanisms in clinical setting might serve as a “negative” biomarker, excluding patients unlikely to benefit from TRAIL-based therapies or present a possibility of pharmacological modulation.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信